DE602007014102D1 - Verfahren zur behandlung oder vorbeugung von symptomen hormoneller veränderungen - Google Patents

Verfahren zur behandlung oder vorbeugung von symptomen hormoneller veränderungen

Info

Publication number
DE602007014102D1
DE602007014102D1 DE602007014102T DE602007014102T DE602007014102D1 DE 602007014102 D1 DE602007014102 D1 DE 602007014102D1 DE 602007014102 T DE602007014102 T DE 602007014102T DE 602007014102 T DE602007014102 T DE 602007014102T DE 602007014102 D1 DE602007014102 D1 DE 602007014102D1
Authority
DE
Germany
Prior art keywords
treating
hormoney
changes
preventing symptoms
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007014102T
Other languages
German (de)
English (en)
Inventor
Hung-Ming Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yung Shin Pharm Industries Co Ltd
Original Assignee
Yung Shin Pharm Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yung Shin Pharm Industries Co Ltd filed Critical Yung Shin Pharm Industries Co Ltd
Publication of DE602007014102D1 publication Critical patent/DE602007014102D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602007014102T 2006-12-13 2007-11-27 Verfahren zur behandlung oder vorbeugung von symptomen hormoneller veränderungen Active DE602007014102D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/638,282 US7645750B2 (en) 2006-12-13 2006-12-13 Method of treating symptoms of hormonal variations
PCT/IB2007/004514 WO2008087491A2 (en) 2006-12-13 2007-11-27 Method for treating or preventing symptoms of hormonal variations

Publications (1)

Publication Number Publication Date
DE602007014102D1 true DE602007014102D1 (de) 2011-06-01

Family

ID=39528142

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007014102T Active DE602007014102D1 (de) 2006-12-13 2007-11-27 Verfahren zur behandlung oder vorbeugung von symptomen hormoneller veränderungen

Country Status (11)

Country Link
US (3) US7645750B2 (enExample)
EP (1) EP2101781B1 (enExample)
JP (1) JP4643742B2 (enExample)
KR (1) KR101435695B1 (enExample)
CN (2) CN102697785B (enExample)
AT (1) ATE506065T1 (enExample)
CA (1) CA2671954C (enExample)
DE (1) DE602007014102D1 (enExample)
MY (1) MY162095A (enExample)
TW (1) TWI330083B (enExample)
WO (1) WO2008087491A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US8631151B2 (en) 2006-05-18 2014-01-14 Intel Corporation Techniques for guaranteeing bandwidth with aggregate traffic
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
AU2007333656A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
US20110065628A1 (en) * 2007-08-27 2011-03-17 University Of Virginia Patent Foundation Medication Combinations for the Treatment of Alcoholism and Drug Addiction
US8420624B2 (en) * 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
CN102016571A (zh) 2008-02-28 2011-04-13 弗吉尼亚大学专利基金会 血清素转运体基因与酗酒的治疗
BR112012022052B1 (pt) * 2010-03-02 2021-06-29 Fervent Pharmaceuticals, Llc Uso de dextrometorfano ou dextorfano e uso de dextrometorfano e dextrofano e gabapentina
US8461102B2 (en) 2010-03-02 2013-06-11 George E. Royster, JR. Methods and compositions for treating and preventing symptoms of hormonal variations
CA2803006A1 (en) * 2010-06-30 2012-01-26 Victoria Link Ltd. Methods and compositions for treatment of multiple sclerosis
AU2011274355B2 (en) 2010-07-02 2016-10-27 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
CN103596571A (zh) * 2011-05-10 2014-02-19 刘垂玗 用于治疗失眠的方法
WO2013036721A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
WO2015013285A2 (en) 2013-07-22 2015-01-29 Ohio State Innovation Foundation Methods for reducing the occurrence of hot flashes
JP6038416B1 (ja) * 2015-04-07 2016-12-07 株式会社明治 火照り抑制剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096254A (en) 1976-05-10 1978-06-20 Richardson-Merrell Inc. Method of treating the symptoms of menopause and osteoporosis
FR2358892A1 (fr) 1976-07-19 1978-02-17 Ile De France N(1'-allyl 2'-pyrrolidylmethyl)2,3-dimethoxy 5-sulfamoyl benzamide, ses derives
US5654011A (en) * 1996-07-30 1997-08-05 Energetics, Inc. Dietary supplements
AU9621598A (en) 1997-10-20 1999-05-10 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
FR2779579B1 (fr) * 1998-06-09 2000-08-25 Thomson Csf Dispositif de commande optique pour l'emission et la reception d'un radar large bande
ATE359068T1 (de) 1999-07-22 2007-05-15 Univ Rochester Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
US6613792B1 (en) 1999-08-02 2003-09-02 Designed Nutritional Products, Inc. Treatment of premenstrual syndrome and menopause
US6358944B1 (en) * 1999-08-13 2002-03-19 Vela Pharmaceuticals, Inc. Methods and compositions for treating generalized anxiety disorder
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
SK12012003A3 (en) * 2001-03-29 2004-10-05 Bristol Myers Squibb Co Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
US20040259850A1 (en) * 2001-10-31 2004-12-23 Alves Stephen E. Method for treating or preventing symptoms of hormonal variation including hot flashes
CN1465348A (zh) 2002-07-05 2004-01-07 冯威健 复方消融合剂及其在用作制备治疗肿瘤药物上的应用
CA2494109A1 (en) * 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
RU2340333C2 (ru) * 2002-08-15 2008-12-10 Вайет Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции
JP2006514633A (ja) * 2002-11-26 2006-05-11 アレックザ ファーマシューティカルズ， インコーポレイテッド 吸入によって送達される抗精神病薬を用いた頭痛の治療
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1753460A2 (en) * 2004-05-11 2007-02-21 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
EP1758600A4 (en) * 2004-06-04 2008-03-05 Mood Man Sciences Llc METHOD AND COMPOSITIONS FOR TREATING MUTUAL DISORDER
TW200631584A (en) 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations

Also Published As

Publication number Publication date
TW200825082A (en) 2008-06-16
TWI330083B (en) 2010-09-11
MY162095A (en) 2017-05-31
KR20090103876A (ko) 2009-10-01
CA2671954C (en) 2012-01-03
WO2008087491A8 (en) 2008-10-30
CN102697785B (zh) 2015-02-18
CN101588804B (zh) 2012-09-05
WO2008087491A3 (en) 2008-12-18
EP2101781B1 (en) 2011-04-20
KR101435695B1 (ko) 2014-09-02
EP2101781A4 (en) 2010-02-10
WO2008087491A2 (en) 2008-07-24
US20100093762A1 (en) 2010-04-15
US7645750B2 (en) 2010-01-12
US20080146541A1 (en) 2008-06-19
CA2671954A1 (en) 2008-07-24
US20150246056A1 (en) 2015-09-03
EP2101781A2 (en) 2009-09-23
ATE506065T1 (de) 2011-05-15
CN102697785A (zh) 2012-10-03
JP2010522137A (ja) 2010-07-01
CN101588804A (zh) 2009-11-25
JP4643742B2 (ja) 2011-03-02

Similar Documents

Publication Publication Date Title
ATE506065T1 (de) Verfahren zur behandlung oder vorbeugung von symptomen hormoneller veränderungen
DK1691892T3 (da) Anbrudsbestandig, coekstruderet doseringsform, der indeholder et aktivt middel og et modvirkende middel, og fremgangsmåde til fremstilling af samme
ATE469895T1 (de) Cgrp-rezeptorantagonisten
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ATE534752T1 (de) Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
DE602007007211D1 (de) Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1
MA32907B1 (fr) Régime posologique d'un agoniste du récepteur s1p
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA200870424A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
MX2009006304A (es) Nuevos compuestos de oxadiazol.
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
EA200900581A1 (ru) Способ лечения демиелинизирующего заболевания (варианты), способ стимулирования ремиелинизации, доставочное устройство (варианты) и набор, способ инструктирования больного, страдающего демиелинизирующим заболеванием
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
UA100877C2 (ru) Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3)
ATE478661T1 (de) Verfahren zur reduzierung der angiogenese
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
EA201290851A1 (ru) Способы и композиции для лечения или предупреждения симптомов гормональных изменений
ATE450256T1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
MX385316B (es) Compuestos de morfinano.
ATE421518T1 (de) Dihydrochinazolinone als 5ht-modulatoren
WO2007061868A3 (en) Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors